Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS):...

Area of Science:

• Neurology
• Clinical Pharmacology
• Pain Management

Background:

• Cryptogenic sensory polyneuropathy (CSPN) is a prevalent, progressive neuropathy causing significant pain.
• Current treatments lack comparative data on efficacy and tolerability for CSPN pain.
• Antiepileptics, antidepressants, and sodium channel blockers are commonly used but their comparative effectiveness is unknown.

Purpose of the Study:

• To compare the effectiveness and tolerability of four medications for neuropathic pain in CSPN patients.
• To identify the optimal medication for pain reduction and patient adherence in CSPN.

Main Methods:

• A Bayesian adaptive, open-label randomized clinical trial involving 402 participants with CSPN.
• Participants (age ≥30, pain score ≥4) were randomized to nortriptyline, duloxetine, pregabalin, or mexiletine.
• The primary outcome was a utility function combining pain reduction (≥50% efficacy) and medication discontinuation rates.

Main Results:

• Nortriptyline (0.81 utility) and duloxetine (0.80 utility) demonstrated higher utility than pregabalin (0.69 utility) and mexiletine (0.58 utility).
• Nortriptyline had a 52% probability of being the most effective, followed by duloxetine (43%).
• Efficacy rates were 25.4% for nortriptyline, 23.0% for duloxetine, 15.1% for pregabalin, and 20.3% for mexiletine.

Conclusions:

• Nortriptyline and duloxetine are more effective and better tolerated than pregabalin and mexiletine for CSPN pain.
• While no single medication was clearly superior, nortriptyline and duloxetine offer a better balance of efficacy and tolerability.
• These findings provide crucial comparative data for managing neuropathic pain in CSPN.